NCT00071890View on ClinicalTrials.gov

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

PHASE2CompletedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

HIV Infections

Interventions

DRUG

Interleukin 2

Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)

DRUG

HAART

HAART from week 0 to week 24

DRUG

Treatment interruption

HAART is interrupted from week 24 in both arms

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

Hospital Henri Mondor, Créteil

All Listed Sponsors

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00071890 - Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx | Biotech Hunter | Biotech Hunter